Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CRB-601 |
Synonyms | |
Therapy Description |
CRB-601 is a monoclonal antibody that targets ITGAV (integrin alphaVbeta8) and inhibits its interaction with L-TGFbeta, which potentially increases antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 706). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CRB-601 | CRB601|CRB601 | CRB-601 is a monoclonal antibody that targets ITGAV (integrin alphaVbeta8) and inhibits its interaction with L-TGFbeta, which potentially increases antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 706). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06603844 | Phase Ib/II | CRB-601 + unspecified PD-1 antibody CRB-601 | First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor. | Not yet recruiting | USA | GBR | 0 |